Mirum reports Q1 sales of $159.9M, raises 2026 guidance to $660-680M, announces trial wins

Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

• high

  Q1 2026 net product sales reached $159.9M, driven by LIVMARLI growth of 55% year-over-year to $113.8M. Full-year 2026 revenue guidance raised to $660-680M, reflecting strong commercial momentum across the portfolio.

  Exhibit 99.1 verify on EDGAR →
• high

  Volixibat Phase 2b VISTAS study in primary sclerosing cholangitis met its primary endpoint. Full results to be presented at EASL on May 30, with U.S. NDA submission expected in H2 2026.

  Exhibit 99.1 verify on EDGAR →
• high

  Brelovitug Phase 2b portion of AZURE-1 study in chronic hepatitis delta virus met its primary endpoint. Phase 3 enrollment complete in AZURE-1 and AZURE-4 studies, with topline results expected in H2 2026.

  Exhibit 99.1 verify on EDGAR →